Agents for computational biology are advancing rapidly, but evals are lagging. Current benchmarks can be overly prescriptive. Full analysis vignettes are hard to verify. We introduce CompBioBench: 100 diverse, challenging, verifiable tasks + benchmark general-purpose agents. 1/9
@dwarkesh_sp Interesting argument @dwarkesh_sp. But in this hyper-inequal world where capital elites hoard nearly all gains, who sustains the demand? Ultra-wealthy can't realistically consume exponentially more to match the inequality they benefit from.
1/ ๐จToday history in AI ๐ป+ biology ๐งฌwas made!
CZI led by Mark Zuckerberg + Priscilla Chan who've admirably committed tens of billions (and the entirety of their wealth to CZI) has acquired Lux family co Evolutionary Scaleโโjust 2yrs after it's founding at a great multiple...
I am thrilled to announce that @RecursionPharma has entered into a definitive agreement to combine with @Exscientia โ bringing together our high throughput target biology, foundation models & supercomputing w/ Exscientiaโs generative #AI drug design & #chemistry #automation.
Whatโs ahead: Our shared portfolio in #oncology, rare disease, & infectious disease expect to have ~10 clinical readouts in the next ~18 months w/ peak sales opportunities of $1B+ for most if successful. Our shared #pharma partnerships include: @Roche@Genentech, @Sanofi, @Bayer, and @EMDGroup, leading to potentially $200m in milestone payments over the next 2 years & the potential for $20B+ in combined milestones.
The #TechBio future is here. $EXAI + $RXRX.
Review important and required disclosure related to this information here https://t.co/mMKZPhiZf4